The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line
A study of ibrutinib-rituximab plus short course R-HCVAD/R-MTX for previously untreated, young mantle cell lymphoma (MCL) patients was presented by M. Wang at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, his colleague Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the findings.
